nucleosid
polym
natur
occur
molecul
wide
area
function
cell
biolog
probabl
best
known
function
role
storag
inform
dna
energi
atp
cell
use
inform
via
transcript
translat
rna
enzymat
reaction
nad
signal
transduct
system
camp
ligand
purinerg
receptor
surpris
therefor
chemist
consid
nucleosid
analog
potenti
rich
sourc
biolog
activ
molecul
three
main
field
research
explor
past
involv
develop
nucleosid
analog
antitumor
antivir
agent
ligand
receptor
antitumor
antivir
nucleosid
meant
kill
cell
virus
mainli
via
interact
metabolit
dna
synthesi
nucleosid
develop
ligand
protein
receptor
consid
agonist
antagonist
receptor
may
broad
applic
human
diseas
first
seri
nucleosid
analog
describ
chapter
antivir
nucleosid
field
cover
nucleosid
drug
market
first
antivir
compound
discov
methisazon
contrast
evolut
therapeut
area
antivir
research
develop
rather
slowli
life
cycl
virus
close
associ
cellular
metabol
virus
local
intracellularli
possess
viral
encod
gene
acut
viral
infect
prevent
develop
effect
vaccin
chang
sinc
discoveri
retroviru
caus
agent
acquir
immun
defici
syndrom
aid
antivir
agent
discov
use
screen
program
recent
ration
drug
design
enter
field
case
base
lead
compound
discov
approach
classic
antivir
compound
nucleosid
analog
structur
similar
natur
nucleosid
structur
idu
zidovudin
similar
thymidin
fig
idu
viru
agent
use
clinic
treatment
herp
kerat
zidovudin
nucleosid
nucleosid
idu
zidovudin
import
impact
develop
antivir
drug
idu
long
model
compound
develop
new
agent
observ
simpl
nucleosid
zidovudin
could
slow
evolut
aid
given
import
stimulu
antivir
research
sinc
specif
viral
enzym
identifi
use
develop
new
select
antivir
agent
import
mileston
field
discoveri
phosphon
nucleosid
treatment
cytomegaloviru
cmv
human
viru
hiv
hepat
b
viru
hbv
infect
dr
made
signific
contribut
class
compound
describ
unit
discoveri
phosphon
nucleosid
antivir
agent
demonstr
possibl
circumv
first
step
metabol
activ
nucleosid
analog
ie
convers
nucleosid
monophosph
charg
compound
taken
cell
although
effici
antivir
nucleosid
rank
sever
categori
pyrimidin
nucleosid
idu
edu
e
bvdu
tft
see
fig
agent
convert
triphosph
viral
cellular
kinas
sever
herp
virus
code
thymidin
kinas
broader
substrat
specif
human
congen
nucleosid
preferenti
phosphoryl
cell
result
select
antivir
activ
triphosph
modifi
nucleosid
function
substitut
polymeras
modifi
nucleosid
incorpor
dna
interfer
normal
transcript
replic
process
monophosph
tft
also
inhibitor
thymidyl
synthetas
explain
strong
antivir
activ
bvdu
activ
viru
vzv
tft
use
topic
treatment
herp
kerat
adenin
fig
first
exampl
purin
nucleosid
came
market
use
enceph
herp
zoster
immunocompromis
patient
howev
soon
replac
anoth
seri
purin
nucleosid
acycl
sugar
chain
unit
dr
describ
synthesi
repres
acycl
nucleosid
rapidli
deamin
vivo
adenosin
deaminas
search
deaminas
inhibitor
led
discoveri
acyclovir
guanin
acyclovir
remain
standard
treatment
hsv
viru
infect
ganciclovir
use
cmv
infect
acycl
nucleosid
consid
analog
acyclovir
phosphoryl
cell
triphosph
although
compound
purin
nucleosid
phosphoryl
monophosph
thymidinedeoxycytidin
kinas
triphosph
acyclovir
competit
inhibitor
dgtp
viral
dna
polymeras
triphosph
may
also
function
substrat
polymeras
upon
incorpor
acyclovir
dna
triphosph
function
chain
termin
ganciclovir
phosphoryl
cell
viral
encod
protein
kinas
although
agent
broad
activ
spectrum
vzv
cmv
viru
ebv
toxic
bone
marrow
neutropenia
medic
use
restrict
treatment
cmv
infect
immunocompromis
patient
penciclovir
antivir
spectrum
acyclovir
prolong
action
due
higher
intracellular
stabil
triphosph
ribavirin
fig
exampl
purin
nucleosid
broad
antivir
spectrum
dna
well
rna
virus
mainli
activ
influenza
viru
respiratori
syncyti
viru
therapeut
use
treatment
respiratori
syncyti
viru
hepat
c
infect
combin
interferon
hiv
retroviru
mean
genom
rna
viru
first
convert
dna
use
revers
transcriptas
enzym
broader
substrat
specif
cellular
dna
polymeras
properti
use
basi
develop
nucleosid
analog
agent
first
nucleosid
analog
came
market
treatment
hiv
zidovudin
fig
follow
didanosin
zalcitabin
stavudin
lamivudin
abacavir
emtricitabin
fig
nucleosid
analog
interfer
function
revers
transcriptas
convert
intracellularli
triphosph
case
didanosin
abacavir
base
moieti
also
modifi
intracellular
metabol
adenin
guanin
base
respect
function
chain
termin
incorpor
dna
didanosin
zalcitabin
stavudin
consid
dideoxynucleosid
analog
lack
secondari
hydroxyl
group
sugar
moieti
abacavir
exampl
carbocycl
nucleosid
mani
carbocycl
nucleosid
synthes
howev
abacavir
reach
market
antivir
agent
lamivudin
emtricitabin
less
toxic
less
effect
transport
mitochondria
emtricitabin
activ
lamivudin
vitro
hiv
although
effect
depend
addit
lamuvidin
use
hiv
hbv
develop
use
hepat
b
infect
synthesi
gram
quantiti
describ
unit
vivo
activ
drug
depend
way
drug
administ
bioavail
nucleosid
often
high
therefor
prodrug
develop
specif
metabol
nucleosid
allow
one
make
use
enzym
involv
nucleosid
metabol
develop
prodrug
xanthin
oxidas
candid
guanin
nucleosid
solubl
water
analog
diacetyl
deriv
penciclovir
give
blood
plasma
concentr
ten
time
higher
penciclovir
given
oral
prodrug
famciclovir
fig
convert
penciclovir
vivo
esteras
xanthin
oxidas
valaciclovir
cfr
supra
anoth
exampl
prodrug
purin
nucleosid
acyclovir
develop
prodrug
acyclovir
absorb
readili
intestin
make
use
stereospecif
transport
system
rapidli
hydrolyz
absorpt
prodrug
famciclovir
valaciclovir
use
treatment
system
hsv
vzv
infect
nucleosid
phosphon
fig
compos
base
phosphon
group
sugar
mimic
compound
current
market
glycosid
bond
enzymat
chemic
stabl
regular
nucleosid
nucleosid
phosphon
need
phosphoryl
diphosph
cellular
enzym
show
activ
broad
rang
virus
well
absorb
given
oral
administ
prodrug
cidofovir
activ
herp
adeno
polyoma
papilloma
pox
virus
use
treatment
cmv
retin
aid
adefovir
activ
retrovirus
hepadnavirus
herp
virus
use
prodrug
form
adefovir
dipivoxil
treatment
hbv
infect
tenofovir
activ
retrovirus
hepadnavirus
use
prodrug
form
tenofovir
disoproxil
treatment
hiv
infect
nucleosid
phosphon
import
characterist
long
action
time
mean
requir
much
less
frequent
dose
nucleosid
field
antivir
nucleosid
still
expand
mani
new
compound
develop
andor
research
phase
mani
infecti
virus
still
wait
seri
new
nucleosid
nucleotid
analog
treatment
perhap
strike
exampl
papilloma
virus
hepat
c
virus
sever
papilloma
virus
induc
tumor
nucleosid
analog
may
also
prevent
cancer
hepat
c
infect
worldwid
problem
also
common
caus
hepatocellular
carcinoma
anoth
import
direct
investig
treatment
pox
viru
infect
variola
viru
caus
smallpox
could
use
effici
bioterrorist
weapon
hemorrhag
fever
virus
may
becom
problem
climat
chang
ebola
viru
rabi
viru
among
deadli
virus
infect
human
influenza
virus
caus
epidem
pandem
human
coronaviru
sever
acut
respiratori
syndrom
may
lead
acut
breath
problem
mortal
mani
virus
lead
gastrointestin
infect
eg
reoviru
caus
diarrhea
chemic
mani
opportun
develop
new
antivir
agent
nucleosid
field
nucleosid
analog
current
market
sever
drawback
lot
room
new
safer
compound
exampl
one
might
ask
long
acyclovir
remain
gold
standard
treatment
herp
viru
infect
activ
spectrum
broad
compound
potent
mode
action
antivir
nucleosid
similar
new
nucleosid
analog
emerg
target
intracellular
enzym
exert
antivir
effect
mani
area
nucleosid
chemistri
still
need
evalu
potenti
gener
new
antivir
compound
although
sever
compound
structur
use
antivir
agent
nucleosid
analog
remain
import
class
antivir
singl
therapi
combin
therapi
simpl
reason
effect
agent
make
break
coval
bond
